Efficacy and Safety of inotuzumab ozogamicin (CMC-544) for the Treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: A Systematic Review and Meta-Analysis

Publication date: Available online 17 December 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Xueqian Li, Meng Zhou, Jiaqian Qi, Yue Han

Source: Clinical Lymphoma Myeloma and Leukemia - December 17, 2020 Category: Cancer & Oncology Source Type: research